The molecular pathology at Work: Metformin and Variability in Glycemic Control

sikandar hayat khan; Muhammad Qaiser Alam Khan; Asma Hayat; Asif Ali; Sajida Shaheen; Muhammad Younis; Muhammad Anwar; Eijaz Ghani

doi:10.51253/pafmj.v74i2.12070

Authors

sikandar hayat khan Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Muhammad Qaiser Alam Khan Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi
Asma Hayat Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi
Asif Ali Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi
Sajida Shaheen Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi
Muhammad Younis Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi
Muhammad Anwar Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi
Eijaz Ghani Commandant, Consultant Virologist, Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi

DOI:

https://doi.org/10.51253/pafmj.v74i2.12070

Keywords:

Metformin, Metformin resistance, metformin response variability, pharmacokinetics of metformin, pharma-cogenetics of metformin, Type 2 Diabetes Mellitus

Abstract

Optimized management of type-2 diabetes mellitus (T2DM) remains a challenge not just because micro and microangiopathies’, chronic kidney disease, and infections related to poor cellular immunity. Methodology to manage T2DM remains in need for evolution to curb disease and help manage economy of diabetes care. Metformin remains the frontline soldier against T2DM. However, optimized and evidence-based use of metform for managing T2DM in clinics needs better molecular analytics to micro-precise medical management. We evaluated 353 manuscripts to finally shortlisted 45 reviews and RCTs using PRISMA guidelines from Google Scholar, PubMed and Cochrane Reviews. This systematic review attempted to identify the role of pharmacokinetic, pharmacogenomic, epigenetic and mitochondrial factors which can lead to sub-optimal diabetes management, metformin resistance and mutations which could lead to poor to no response to medicine. The most common mutations and polymorphisms in solute channels were observed to reduce the therapeutic efficacy/resistance

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2014; 2(1): 56-64. https://doi.org/10.1016/S2213-8587(13)70112-8

Bailey CJ, Day C. The future of new drugs for diabetes management. Diabetes Res Clin Pract. 2019; 155: 107785.

https://doi.org/10.1016/j.diabres.2019.107785

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 Jan; 38(1): 140-9.

https://doi.org/10.2337/dc14-2441. PMID: 25538310

Rutter GA, Chimienti F. SLC30A8 mutations in type 2 diabetes. Diabetologia. 2015 Jan; 58(1): 31-6.

https://doi. Org/10.1007/s00125-014-3405-7

Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017 May; 60(5): 769-777. https://doi.org/10.1007/s00125-017-4226-2

Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018 Nov; 50(11): 1505-1513.

https://doi.org/10.1038/s41588-018-0241-6

Alam F, Kamal MA, Islam MA, Banu S. Current Genetic and Epigenetic Insights into Type 2 Diabetes Mellitus. Endocr Metab Immune Disord Drug Targets. 2019; 19(6): 717-718.

https://doi.org/10.2174/187153031906190724104004

Gloyn AL, Drucker DJ. Precision medicine in the management of type 2 diabetes. Lancet Diabetes Endocrinol. 2018 Nov;6(11):891-900. https://doi.org/10.1016/S2213-8587(18)30052-4

Park JE, Jeong GH, Lee IK, Yoon YR, Liu KH, Gu N, Shin KH. A,et al Pharmacometabolomic Approach to Predict Response to Metformin in Early-Phase Type 2 Diabetes Mellitus Patients. Molecules. 2018 Jun 29; 23(7): 1579. PMID: 29966242

https://doi.org/10.3390/molecules23071579

Clement Y, Singh S, Motilal S, Maharaj R, Nunez-Smith M. A Protocol for the Study of Polymorphisms and Response to Metformin in Patients with Type 2 Diabetes in Trinidad. Ethn Dis. 2020 Apr 2; 30(Suppl-1): 211-216.

https://doi.org/10.18865/ed.30.S1.211

García-Escalante MG, Suárez-Solís VM, López-Avila MT, Pinto-Escalante Ddel C, Laviada-Molina H. Efecto de los polimorfismos Gly972Arg del gen IRS1, SNP43 del gen CAPN10 y Prol2Ala del gen PPARG2 sobre la falla secundaria a sulfonilureas y metformina en pacientes con diabetes tipo 2 de Yucatán, Mexico [Effect of the Gly972Arg, SNP43 and Prol2Ala polymorphisms of the genes IRS1, CAPN10 and PPARG2 on secondary failure to sulphonylurea and metformin in patients with type 2 diabetes in Yucatán, México]. Invest Clin. 2009 Mar; 50(1) :65-76. Spanish. PMID: 19418728.

Khan SH, Sarwar U. Newer molecular insights into type-2 diabetes mellitus. J Pak Med Assoc. 2020 Jun; 70(6): 1072-1075. https://doi.org/10.5455/JPMA.20728

Kajbaf F, Lalau JD. Mortality rate in so-called "metformin-associated lactic acidosis": a review of the data since the 1960s. Pharmacoepidemiol Drug Saf. 2014 Nov; 23(11) :1123-7. https://doi.org/10.1002/pds.3689

Peng A, Gong C, Xu Y, Liang X, Chen X, Hong W, Yan J et al. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis. Front Public Health. 2023 Jul 21;11:1183879.

https://doi.org/10.3389/fpubh.2023.1183879

Zhang X, Yang S, Chen J, Su Z. Unraveling the Regulation of Hepatic Gluconeogenesis. Front Endocrinol (Lausanne). 2019 Jan 24;9:802.

https://doi.org/10.3389/fendo.2018.00802

Chen X, Wang DD, Li ZP. Time course and dose effect of metformin on weight in patients with different disease states. Expert Rev Clin Pharmacol. 2020 Oct; 13(10): 1169-1177. https://doi.org/10.1080/17512433.2020.1822164

Shields BM, Dennis JM, Angwin CD, Warren F, Henley WE, Farmer AJ, Sattar N, Holman RR, Jones AG, Pearson ER, Hattersley AT et al; TriMaster Study group. Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. Nat Med. 2023 Feb; 29(2): 376-383. https://doi.org/10.1038/s41591-022-02120-7

Guo Z, Priefer R. Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview. Diabetes Metab Syndr. 2021 Sep-Oct; 15(5): 102239. https://doi.org/10.1016/j.dsx.2021.102239

Zhang C, Zhang R. More effective glycaemic control by metformin in African Americans than in Whites in the prediabetic population. Diabetes Metab. 2015 Apr; 41(2): 173-5.

https://doi.org/10.1016/j.diabet.2015.01.003

Sam WJ, Roza O, Hon YY, Alfaro RM, Calis KA, Reynolds JC, Yanovski JA et al. Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. J Clin Pharmacol. 2017 Feb; 57(2): 219-229.

https://doi.org/10.1002/jcph.796

Hansen CS, Lundby-Christiansen L, Tarnow L, Gluud C, Hedetoft C, Thorsteinsson B, Hemmingsen B, Wiinberg N, Sneppen SB, Lund SS, Krarup T, Madsbad S, Almdal T, Carstensen B, Jørgensen ME et al; CIMT study group. Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial. Cardiovasc Diabetol. 2020 Sep 26; 19(1): 150.

https://doi.org/10.1186/s12933-020-01131-3

Pearson ER. Pharmacogenetics and target identification in diabetes. Curr Opin Genet Dev. 2018 Jun; 50: 68-73.

https://doi.org/10.1016/j.gde.2018.02.005

Maxwell TJ, Franks PW, Kahn SE, Knowler WC, Mather KJ, Florez JC, Jablonski KA et al; and for the Diabetes Prevention Program Research Group. Quantitative trait loci, G×E and G×G for glycemic traits: response to metformin and placebo in the Diabetes Prevention Program (DPP). J Hum Genet. 2022 Aug; 67(8): 465-473. https://doi.org/10.1038/s10038-022-01027-y

Out M, Becker ML, van Schaik RH, Lehert P, Stehouwer CD, Kooy A. A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT. Pharmacogenomics. 2018 Jun 1; 19(8): 715-726.

https://doi.org/10.2217/pgs-2018-0010

Weksler-Zangen S. Is Type 2 Diabetes a Primary Mitochondrial Disorder? Cells. 2022 May 12; 11(10): 1617.

https://doi.org/10.3390/cells11101617

Arslanian S, El Ghormli L, Haymond MH, Chan CL, Chernausek SD, Gandica RG, Gubitosi-Klug R, Levitsky LL, Siska M, Willi SM et al; TODAY Study Group. Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure. Pediatr Diabetes. 2020 Jun; 21(4): 575-585.

https://doi.org/10.1111/pedi.12998

Garfunkel D, Anagnostou EA, Aman MG, Handen BL, Sanders KB, Macklin EA, Chan J, Veenstra-VanderWeele J et al. Pharmacogenetics of Metformin for Medication-Induced Weight Gain in Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2019 Aug; 29(6): 448-455.

https://doi.org/10.1089/cap.2018.0171

Li S, Xu B, Fan S, Kang B, Deng L, Chen D, Yang B, Tang F, He Z, Xue Y, Zhou JC et al. Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin. Expert Rev Clin Pharmacol. 2022 Sep; 15(9): 1107-1117.

https://doi.org/10.1080/17512433.2022.2118714

Florez JC. The pharmacogenetics of metformin. Diabetologia. 2017 Sep; 60(9): 1648-1655.

https://doi.org/10.1007/s00125-017-4335-y

Pradana DA, Kristin E, Nugrahaningsih DAA, Nugroho AK, Pinzon RT. Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review. Curr Diabetes Rev. 2023 Aug 7. https://doi.org/10.2174/1573399820666230807145202

Damanhouri ZA, Alkreathy HM, Alharbi FA, Abualhamail H, Ahmad MS. A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes. Int J Med Sci. 2023 Jan 1; 20(1): 142-150.

https://doi.org/10.7150/ijms.77206

Chan P, Shao L, Tomlinson B, Zhang Y, Liu ZM. Metformin transporter pharmacogenomics: insights into drug disposition-where are we now? Expert Opin Drug Metab Toxicol. 2018 Nov; 14(11): 1149-1159.

https://doi.org/10.1080/17425255.2018.1541981

Giordo R, Posadino AM, Mangoni AA, Pintus G. Metformin-mediated epigenetic modifications in diabetes and associated conditions: Biological and clinical relevance. Biochem Pharmacol. 2023 Sep; 215: 115732.

https://doi.org/10.1016/j.bcp.2023.115732

Mofo Mato EP, Guewo-Fokeng M, Essop MF, Owira PMO. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review. Medicine (Baltimore). 2018 Jul; 97(27): e11349.

https://doi.org/10.1097/MD.0000000000011349

Nasykhova YA, Tonyan ZN, Mikhailova AA, Danilova MM, Glotov AS. Pharmacogenetics of Type 2 Diabetes-Progress and Prospects. Int J Mol Sci. 2020 Sep 18; 21(18): 6842.

https://doi.org/10.3390/ijms21186842

Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, Pearson ER, Wagner MJ, Buse JB, Motsinger-Reif AA et al; MetGen Investigators; ACCORD/ACCORDion Investigators. Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. Diabetes. 2018 Jul; 67(7): 1428-1440.

https://doi.org/10.2337/db17-1164

Kölz C, Schaeffeler E, Schwab M, Nies AT. Genetic and Epigenetic Regulation of Organic Cation Transporters. Handb Exp Pharmacol. 2021; 266: 81-100.

https://doi.org/10.1007/164_2021_450. PMID: 33674913

Florez JC. Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? Diabetologia. 2017 May; 60(5): 800-807. https://doi.org/10.1007/s00125-017-4227-1

3Baye AM, Fanta TG, Siddiqui MK, Dawed AY. The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review. Front Genet. 2021 Jun 14; 12: 675053.

https://doi.org/10.3389/fgene.2021.675053

Singh S, Usman K, Banerjee M. Pharmacogenetic studies update in type 2 diabetes mellitus. World J Diabetes. 2016 Aug 10; 7(15): 302-15. https://doi.org/10.4239/wjd.v7.i15.302

Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE. The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM). Inflammopharmacology. 2023 Aug; 31(4): 1751-1760.

https://doi.org/10.1007/s10787-023-01255-4

Zhou T, Xu X, Du M, Zhao T, Wang J. A preclinical overview of metformin for the treatment of type 2 diabetes. Biomed Pharmacother. 2018 Oct; 106: 1227-1235.

https://doi.org/10.1016/j.biopha.2018.07.085

Mannar V, Boro H, Patel D, Agstam S, Dalvi M, Bundela V et al. Epigenetics of the Pathogenesis and Complications of Type 2 Diabetes Mellitus. touchREV Endocrinol. 2023 May;1 9(1): 46-53. https://doi.org/10.17925/EE.2023.19.1.46

Scheen AJ. Precision medicine: The future in diabetes care? Diabetes Res Clin Pract. 2016 Jul;117:12-21.

https://doi.org/10.1016/j.diabres.2016.04.033

Sciannimanico S, Grimaldi F, Vescini F, De Pergola G, Iacoviello M, Licchelli B, Guastamacchia E, Giagulli VA, Triggiani V et al. Metformin: Up to Date. Endocr Metab Immune Disord Drug Targets.2020;20(2):172-181. PMID: 31670618.

https://doi.org/10.2174/1871530319666190507125847

RISE Consortium. Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care. 2018 Aug; 41(8): 1717-1725.

https://doi.org/10.2337/dc18-0787

Adeva-Andany MM, Rañal-Muíño E, Fernández-Fernández C, Pazos-García C, Vila-Altesor M. Metabolic Effects of Metformin in Humans. Curr Diabetes Rev. 2019; 15(4): 328-339. PMID: 30306875. https://doi.org/10.2174/1573399814666181009125348

Cao G, Gong T, Du Y, Wang Y, Ge T, Liu J et al. Mechanism of metformin regulation in central nervous system: Progression and future perspectives. Biomed Pharmacother. 2022 Dec; 156: 113686. https://doi.org/10.1016/j.biopha.2022.113686

Khodadadi M, Jafari-Gharabaghlou D, Zarghami N. An update on mode of action of metformin in modulation of meta-inflammation and inflammaging. Pharmacol Rep. 2022 Apr; 74(2): 310-322. https://doi.org/10.1007/s43440-021-00334-z

Lehtonen S. SHIPping out diabetes-Metformin, an old friend among new SHIP2 inhibitors. Acta Physiol (Oxf). 2020 Jan;228(1):e13349. https://doi.org/10.1111/apha.13349

Pearson ER. Personalized medicine in diabetes: the role of 'omics' and biomarkers. Diabet Med. 2016 Jun;33(6):712-7.

https://doi.org/10.1111/dme.13075

Chang W, Li W, Li P. The anti-diabetic effects of metformin are mediated by regulating long non-coding RNA. Front Pharmacol. 2023 Nov 20; 14: 1256705. PMID: 38053839; PMCID: PMC10694297. https://doi.org/10.3389/fphar.2023.1256705

Safai N, Suvitaival T, Ali A, Spégel P, Al-Majdoub M, Carstensen B, Vestergaard H, Ridderstråle M; CIMT et al Trial Group. Effect of metformin on plasma metabolite profile in the Copenhagen Insulin and Metformin Therapy (CIMT) trial. Diabet Med. 2018 Jul;3 5(7): 944-953. https://doi.org/10.1111/dme.13636

Preiss D, Rankin N, Welsh P, Holman RR, Kangas AJ, Soininen P, Würtz P, Ala-Korpela M, Sattar N et al. Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study. Diabet Med. 2016 Nov; 33(11): 1569-1574. PMID: 26887663 https://doi.org/10.1111/dme.13097

Rashid M, Shahzad M, Mahmood S, Khan K. Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus. Pak J Med Sci. 2019 Jan-Feb; 35(1): 71-76. https://doi.org/10.12669/pjms.35.1.100

Moeez S, Riaz S, Masood N, Kanwal N, Arif MA, Niazi R, Khalid S, et al. Evaluation of the rs3088442 G> A SLC22A3 gene polymorphism and the role of microRNA 147 in groups of adult Pakistani populations with type 2 diabetes in response to metformin. Canadian Journal of Diabetes. 2019 Mar 1; 43(2): 128-35.

Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, Mefford JA, Wen C, Liang X, Witte J, Brett C, et al. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clinical Pharmacology & Therapeutics. 2014 Sep; 96(3): 370-9.